ArticleScientific reports2024

Narazaciclib, a novel multi-kinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models.

Tao Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.